FUTURE OF HEALTHCARE

RLDatix Completes Acquisition of Allocate Software

RLDatix | September 23, 2021

RLDatix Completes Acquisition of Allocate Software

RLDatix, the international leader in governance, risk and compliance (GRC) solutions for healthcare, announced today the completion of the acquisition of UK-based Allocate Software (“Allocate”), a leading provider of human capital management solutions that help healthcare organisations deliver safe and effective care. The acquisition was previously announced on June 28th, 2021.

 

With the completion of this acquisition, RLDatix cements its position as the global innovator in healthcare GRC, combining its industry leading patient safety, risk, compliance and provider management capabilities with Allocate’s leading workforce management solutions. It also further accelerates Applied Safety IntelligenceTM, the company’s strategy to shift healthcare from reactive risk management to proactive prevention.

 

We’re thrilled to complete the acquisition of Allocate and start the next chapter of our exciting journey together. Covid-19 has reminded us that patient, workforce and organisational safety are inextricably linked, as burnout, well-being of care-givers and overall resilience are challenges felt by healthcare providers around the world. With the acquisition of Allocate, RLDatix is well positioned to continue delivering innovative, scaled and needed solutions that link healthcare GRC and workforce management. Combined, we will make healthcare safer.

Jeff Surges, CEO, RLDatix

 

We have always understood the link between patient safety, the welfare of staff and workforce technology and are very excited to join forces with RLDatix. With increasing demand for care and the ongoing clinician shortage being faced in healthcare we fully expect to positively impact both staff welfare and patient outcomes. We will be able to ensure that resources are planned, supported and truly underpinned by patient safety and quality.

Nick Wilson, CEO, Allocate Software

 

“The combination of RLDatix and Allocate creates an organisation of significant global scale that is poised to drive innovation in healthcare for years to come,” said Vivek Kumar, Partner at Five Arrows Principal Investments. “We look forward to supporting Jeff and his team in this exciting next phase of the company’s growth.” “RLDatix and Allocate are integral to some of the world’s largest healthcare organisations,” added Reid Perper, CIO, Five Arrows Capital Partners. “This combination is uniquely positioned to deliver continued growth while unlocking exciting new opportunities that will benefit customers around the world.”

 

“It has been a pleasure working with RLDatix over the past three years to scale the business through organic and acquisitive growth, helping to solidify its position as a global leader in GRC,” said Naveen Wadhera, Managing Director at TA. “As we continue our partnership, we believe RLDatix and Allocate’s collective learnings and best practices will strengthen the combined company’s competitive positioning and help healthcare organisations around the world provide safer, higher quality, and more efficient care,” added Ethan Liebermann, Managing Director at TA.

 

Each month, 1.2 million staff utilise Allocate solutions to manage their working lives, over 1.4 million temporary staff shifts are filled and over 8 million hours of nursing care is redeployed for safety-related purposes. Worldwide, millions of people are protected by RLDatix software as they navigate the healthcare system, and as organisations shift towards high reliability, the company’s expanding solution set will provide the data and analytics that drive actionable insights and overall improvement.

 

Together, RLDatix and Allocate will be better able to support strategic initiatives across human capital management, patient & health worker safety, and other healthcare operations critical to driving safer, better care for all.

 

About RLDatix

RLDatix is on a mission to change healthcare. We help organisations drive safer, more efficient care by providing governance, risk and compliance tools that drive overall improvement and safety. Our suite of cloud-based software helps organisations report on adverse events, reduce healthcare-acquired infections and ensure patient safety learnings are implemented across the continuum of care. With more than 5,000 customers over 20 countries, RLDatix software protects hundreds of millions of patients around the world. RLDatix is controlled by Five Arrows and TA Associates as major shareholders. For more information, visit www.rldatix.com.

 

About Allocate Software

Allocate Software is a leading international provider of Human Capital Management solutions, supporting the operational and administrative needs of health, care, defence and commercial sectors.

 

In the health and care sector, Allocate is enabling the delivery of safe and effective care at optimal cost, by helping organisations to have the right people in the right place at the right time. With over 800 clients and over two million staff rostered daily, Allocate serves the largest public and private sector institutions around the world. Allocate Software is headquartered in the United Kingdom, with nearly 700 employees, including over 200 in research, development, and product management functions. It provides services and support to its international customer base through regional offices in the UK, Sweden, Germany and Australia. For more information, visit www.allocatesoftware.com.

 

About Five Arrows

Five Arrows Principal Investments (FAPI) and Five Arrows Capital Partners (FACP), together “Five Arrows”, are part of the corporate private equity arm of Rothschild & Co’s Merchant Banking business which manages over €17 billion. Five Arrows is focused on investing in middle-market companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong free cash flow conversion; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology-enabled business services and healthcare.

Spotlight

The UK Government contains a number of ministries known mainly, though not exclusively as departments. These are politically led by a Government Minister who is often a Secretary of State and member of the Cabinet (the executive of the parliament chosen by the prime minister). He or she may also be supported by a number of junior Ministers.


Other News
HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics. Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs? Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely. Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signaled, Life is the leading healthcare end-to-end programmatic platform. Life's automated machine learning and AI allows marketers to quickly create highly-customized segments that classify populations in real-time, and deliver sequential messaging to drive customer actions in the moment and across the health journey. This next generation of the Life platform includes: • Advanced media planning innovations: Life offers an AI-powered forecasting tool used to run simulations to generate predictive performance metrics and intelligent audience insights. This makes it easier for marketers to preview budgets and ideate and adjust tactics to obtain their desired campaign outcomes, all before a single dollar is spent. Each forecast is powered by detailed supply and channel insights, like expected delivery, and campaign performance can be viewed by a variety of dimensions, including creative types, domains/apps, condition categories, healthcare professional specialties, geographies, among others. • Better campaign management with advanced dashboard: An automated and real-time view of line item performance and pacing gives traders a deeper, more granular look into their campaigns, making it easier for them to optimize their spend based on flight delivery and anticipate new incremental opportunities. The dashboard not only surfaces key numbers, but it also includes dynamic performance charts to uncover real-time campaign insights. • Turnkey PMP (private marketplaces) deal builder: Enhanced with turnkey end-to-end functionality, self-serve traders can now enable the deals that they negotiated directly with publishers and/or SSPs through Life's UI, decreasing the time it takes to launch PMPs. "Life was built for the healthcare marketer to simplify and optimize marketing campaigns," said Andrew Stark, CRO of PulsePoint. "Our newest capabilities increase efficiencies through advanced forecasting and real-time performance optimization, enabling more control and enhanced campaign management." Life by PulsePoint provides access to over 110 billion daily impressions across more than 2 million health pages, reaching 1.8M+ opted-in, verified healthcare professionals and over 90% of the online U.S. population. This release is just another step in PulsePoint's journey to deliver personalized messaging at each stage of the health journey using predictive insights built on real-time data. The company was recently acquired by Internet Brands, a KKR portfolio company and owner of WebMD Health Corp. PulsePoint's teams will continue to operate as their own division from their existing hubs in New York, San Francisco, and London. About PulsePoint PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve.

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

Spotlight

The UK Government contains a number of ministries known mainly, though not exclusively as departments. These are politically led by a Government Minister who is often a Secretary of State and member of the Cabinet (the executive of the parliament chosen by the prime minister). He or she may also be supported by a number of junior Ministers.

Resources

Events